Following a successful TAVR* procedure, taking apixaban was not superior to standard antithrombotic therapy for the composite primary outcome, regardless of whether patients originally have an indication for oral anticoagulant (OAC), according to the ATLANTIS** trial.
The cardioprotective drugs metoprolol and candesartan had little benefit on cardiovascular (CV) outcomes when given alongside adjuvant anthracycline treatment in women with early breast cancer and low CV risk, long-term results of the PRADA* trial showed.
Consuming at least one glass of wine, a bottle/can of beer, or a shot of hard liquor appears to be associated with an increased risk of an atrial fibrillation (AFib) episode within 4 hours post-drink, according to the HOLIDAY* Monitors study presented at the ACC.21 Virtual Meeting.
A tailored, progressive rehabilitation programme may improve physical function in older patients hospitalized with acute decompensated heart failure (ADHF), according to results of the REHAB-HF* trial presented at ACC.21.
The SGLT2 inhibitor dapagliflozin did not result in a reduced incidence of organ failure or death in patients with cardiometabolic risk factors who were hospitalized with COVID-19, according to the phase III DARE-19* trial. However, this finding does not support discontinuation of SGLT2 inhibitors in COVID-19 patients.
Taking low-strength aspirin at 81 mg dose daily (also known as baby aspirin) appeared to be as effective as a higher dose of 325 mg for secondary prevention in people with established atherosclerotic cardiovascular disease (ASCVD), with no difference in major bleeding outcomes, according to the ADAPTABLE* trial presented at ACC.21.
The fractional flow reserve (FFR) approach is no better than angiography-guided strategy in patients with multivessel STEMI* undergoing complete revascularization in the head-to-head FLOWER-MI trial**.
Left atrial appendage occlusion (LAAO) added to usual care led to a reduction in ischaemic stroke or non-cerebral systemic embolism following cardiac surgery among patients with atrial fibrillation (AF), according to results of the LAAOS* III trial.
Treatment with the HMG-CoA reductase inhibitor atorvastatin in critically ill patients with COVID-19 did not significantly reduce the primary composite outcome of venous or arterial thrombosis risk, treatment with extracorporeal membrane oxygenation (ECMO), or mortality vs placebo in the INSPIRATION-S study presented at ACC.21.
In hospitalized COVID-19 patients with elevated D-dimer levels who were under stable condition, initial in-hospital anticoagulation using a therapeutic dose of rivaroxaban 20 mg did not improve clinical outcomes compared with standard prophylactic anticoagulation, according to the ACTION* trial presented at ACC.21 Meeting.